van den Bent, Martin <br/><br/>
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.  [electronic resource] 

 -  Journal of neuro-oncology  Jan 2020 
 - 79-89 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-019-03337-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aminopyridines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics<br/>Benzamides<br/>Brain Neoplasms--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Morpholines--administration & dosage<br/>Neoplasm Recurrence, Local--drug therapy<br/>PTEN Phosphohydrolase--genetics<br/>Prognosis<br/>Proto-Oncogene Proteins c-met--genetics<br/>Tissue Distribution<br/>Triazines--administration & dosage